Jed Latkin is CEO & COO & CFO at NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB). They have made 6 open-market trades across 1 company since 2017, most recently 2020-08-14.
CIK 0001554593
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $35K since 2017, never a sale. Across 6 scored buys the stock is down 29.8% at ninety days, and 29.1 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| NAVB | 107,997 | $8K |
Shares reported on the most recent Form 4, priced at the 2020-08-18 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 0% | 17% |
| Avg Move | -14.5% | -33.4% | -29.8% |
| Alpha | -18.8% | -28.9% | -29.1% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NAVB | BUY | 2020-02-20 | 2020-02-20 | $1.08 | $5K | -13.7% | -35.0% | +10.3% |
| NAVB | BUY | 2019-06-05 | 2019-06-07 | $1.26 | $1K | -42.8% | -51.7% | -53.7% |
| NAVB | BUY | 2019-05-16 | 2019-05-17 | $1.45 | $4K | -9.1% | -52.4% | -62.9% |
| NAVB | BUY | 2019-05-13 | 2019-05-15 | $1.80 | $10K | +0.0% | -51.1% | -62.0% |
| NAVB | BUY | 2017-05-30 | 2017-05-31 | $0.44 | $3K | -10.6% | -5.1% | -5.1% |
| NAVB | BUY | 2017-05-19 | 2017-05-23 | $0.45 | $11K | -10.6% | -5.1% | -5.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.